IMIPRAMINE TABLET

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

IMIPRAMINE HYDROCHLORIDE

Tilgjengelig fra:

AA PHARMA INC

ATC-kode:

N06AA02

INN (International Name):

IMIPRAMINE

Dosering :

10MG

Legemiddelform:

TABLET

Sammensetning:

IMIPRAMINE HYDROCHLORIDE 10MG

Administreringsrute:

ORAL

Enheter i pakken:

100/1000

Resept typen:

Prescription

Terapeutisk område:

TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS

Produkt oppsummering:

Active ingredient group (AIG) number: 0103832003; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2010-05-26

Preparatomtale

_IMIPRAMINE (imipramine hydrochloride) _
_Page 1 of 25_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
IMIPRAMINE
Imipramine Hydrochloride Tablets
Tablets, 10 mg, 25 mg, 50 mg and 75 mg, Oral
USP
Antidepressant
AA PHARMA INC
1165 Creditstone Road Unit #1
Vaughan, Ontario
L4K 4N7
www.aapharma.ca/en/
Date of Initial Authorization:
DEC 31, 1975
Date of Revision:
MAY 23, 2023
Submission Control Number: 270511
_IMIPRAMINE (imipramine hydrochloride) _
_Page 2 of 25_
RECENT MAJOR LABEL CHANGES
2 Contraindications
05/2023
7 Warnings and Precautions, Neurologic
05/2023
7 Warnings and Precautions, Ophthalmologic
05/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
...................................................................................................
4
3.
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 4
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.1
Dosage Considerations
...........................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
..........................................